Transition to Adulthood in People With Muscular Dystrophy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age14+
SponsorIRCCS Eugenio Medea

About this trial

The study will involve boys with Duchenne Muscular Dystrophy (DMD), from adolescence to adulthood living in Italy, and their families/ caregivers.

The Investigators want to explore patients' mental health, social cognition and perception of body image as well as patients'and caregivers' ability to adapt to changes related to both the disease and various personal and social needs, through the use of short and simple questionnaires, neuropsychological tests and neurocognitive evaluation in ecological scenarios using Virtual Reality. The desire for autonomy and the awareness of both personal and social difficulties in achieving them put a strain on both patients and their families.Some studies conducted in the USA and in various European countries underline that the transition to adulthood of patients with muscular dystrophy is featured by a good ability to adapt to the more advanced stages of the disease in general; nevertheless, facing the worsening of health entails experiences of anxiety and depression.In this historical phase, clinical trials of gene therapy and gene modulating therapies are involving an increasing number of patients, mainly represented by children in the early phase of the disease. Hence, adolescents and young adults could develop feelings of exclusion from research efforts, losing confidence and hope in any future improvement of their condition, social participation and quality of life.This study could lead to identify strengths and weaknesses in social cognition and psychosocial adaptation; through the evaluation of characteristics of patients/caregivers or exogenous factors influencing higher levels of social adaptation, we ultimately aim to define strategies to improve not only physical (already defined by guidelines) but also psychological care, social cognition and social support in all stages of DMD, particularly in later ones.

Eligibility criteria

Qualifiers

Defined diagnosis of DMD

Age > 14 years

Willingness and ability to comply to study procedures

Comprehension of the study and Signature of the informed consent

Disqualifiers

Clinical history of cerebral palsy, severe intellectual deficit, severe behavioral disturbances

absence of compliance to the studyof the patient and the caregivers.

Trial design

Treatments tested in this trial

  • VIRTUAL REALITY

Treatment groups

250 Participants
are divided into 1 treatment group

Sponsors and collaborators

IRCCS Eugenio Medea

Lead sponsor

University of Padova

Collaborator

IRCCS National Neurological Institute "C. Mondino" Foundation

Collaborator

Istituto Giannina Gaslini - IRCCS

Collaborator

Fondazione Serena Onlus - Centro Clinico NeMO Milano

Collaborator

Centro Clinico NeMO Ancona

Collaborator

IRCCS Fondazione Stella Maris

Collaborator

Università degli Studi di Milano Statale

Collaborator

Centro Clinico NeMO Brescia

Collaborator

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Collaborator

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborator

I.R.C.C.S. Eugenio Medea - Associazione La Nostra Famiglia - Sede di Conegliano

Collaborator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator

Dipartimento di Neuroscienze Rita Levi Montalcini Torino

Collaborator

Università Vita-Salute San Raffaele

Collaborator

Università di Pisa

Collaborator

Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Collaborator

Associazione La Nostra Famiglia Eugenio Medea - Brindisi

Collaborator

Scientific Institute, IRCCS E.Medea, Pasian di Prato

Collaborator

IRCCS Istituto delle Scienze Neurologiche di Bologna

Collaborator